FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it - Boing Boing
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's Spravato (Esketamine) nasal spray as a "monotherapy" treatment for major depressive disorder.
Comments